What are the recommended treatment options after disease progression on first‑line osimertinib in a patient with EGFR‑mutated non‑small cell lung cancer, including systemic therapy and management of brain metastases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: February 24, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

When should combination osimertinib (osimertinib) with chemotherapy be given to a patient with stage 4 non-small cell lung cancer (NSCLC) and an epidermal growth factor receptor (EGFR) exon 19 deletion who has progressed on osimertinib (osimertinib) monotherapy?

How many sessions of osimertinib (Tagrisso) are recommended before reassessing a patient with stage 4 non-small cell lung cancer (NSCLC) and an epidermal growth factor receptor (EGFR) exon 19 deletion?

What are the recommended management options after disease progression on first‑line osimertinib in a patient with EGFR‑mutated non‑small cell lung cancer?

What is the best treatment for Epidermal Growth Factor Receptor (EGFR) mutated lung cancer, Osimertinib (Tagrisso) or Amivantamab and Lazertinib (generic names)?

What are the treatment options for metastatic non-small cell lung cancer with an epidermal growth factor receptor (EGFR) mutation?

Can the Richmond Agitation‑Sedation Scale (RASS) be used to assess sedation and agitation in pediatric patients, including critically ill children in the PICU?

In an adult with acute intracerebral or subarachnoid hemorrhage and a presenting systolic blood pressure of 150–220 mmHg, what is the target blood pressure and the recommended first‑line antihypertensive agents?

How do you differentiate upper motor neuron (UMN) lesions from lower motor neuron (LMN) lesions?

Can the Critical‑Care Pain Observation Tool (CPOT) be used in pediatric patients?

Does an IgE‑mediated allergy to codeine imply a significant risk of cross‑reactivity with oxycodone, necessitating avoidance of oxycodone?

How is peripartum cardiomyopathy diagnosed and managed in a woman who develops new‑onset heart‑failure symptoms during the last month of pregnancy through five months postpartum?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.